Fylde and Wyre CCG Medicines Optimisation

Click each header to expand its content

Fylde and Wyre medicines RAG list

Application forms

Medicines commissioning policies

Actipatch for pain management 0.6 MB234
Albiglutide for type-2 diabetes mellitus 0.3 MB169
Alprostadil Cream For ED 0.3 MB151
Azelastine Fluticasone (Dymista) Nasal Spray 0.1 MB249
Bazedoxifene for oestrogen deficiency symptoms 0.3 MB159
Botulinum Toxin A for Spasticity and Contracture of the joint 0.3 MB174
Brimonidine For Erythema Of Rosacea 0.1 MB149
Brivaracetam for epilepsy 0.3 MB149
Budesonide multimatrix MMX 9mg prolonged release tablets 0.2 MB211
Certolizumab For Psoriatic Arthritis 0.1 MB129
Co-Proxamol For pain management 0.3 MB305
Co-trimoxazole for the prophylaxis of pneumocystis jirovecii (pneumocystis carinii) infections 0.3 MB165
Co-trimoxazole Prophylaxis of Primary and Secondary Spontaneous Bacterial Peritonitis (SBP) 0.1 MB171
Colesevelam (Cholestagel® ) For combination or monotherapy for familial hypercholesterolaemia 0.3 MB145
Colistimethate sodium/Colistin sulfomethate sodium (Colomycin® ) For non-Cystic Fibrosis in Patients with Bronchiectasis Colonised with Pseudomonas Aeruginosa 0.2 MB122
Conditions for which over the counter items should not routinely be prescribed in primary care 0.9 MB291
Daily selective serotonin re-uptake inhibitors (SSRIs) for the treatment of premature ejaculation (PE) 0.2 MB113
Dapoxetine for the treatment of premature ejaculation (PE) 0.2 MB130
Denosumab for GIO 0.2 MB104
Dulaglutide for the treatment of Type II Diabetes Mellitus in adults 0.3 MB172
Eflornithine-cream-for-facial-hirsutism 0.2 MB161
Eltrombopag For Thrombocytopenia In Hepatitis C 0.1 MB108
Eslicarbazepine For Focal Seizures 0.1 MB137
Evolocumab (Repatha SureClick® ) For prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin 0.1 MB143
Ferric Maltol 30mg Capsules in Adults for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease 0.3 MB140
Fluorouracil-5-cream-for-basal-cell-carcinomas 0.1 MB113
Gluten-Free-Food-Products 0.3 MB155
Guanfacine-for-ADHD 0.3 MB128
Imiquimod-5-cream-for-basal-cell-carcinomas 0.2 MB134
Insulin Degludec And Liraglutide 0.2 MB132
Insulin-Aspart-for-Diabetes-Mellitus 0.3 MB148
Insulin-Degludec-for-DM 0.3 MB146
Insulin-Detemir-for-DM 0.2 MB111
Insuline-Glargine-for-T1DM 0.3 MB127
Insuline-Glargine-for-T2DM 0.3 MB124
Invicorp-injection-for-erectile-dysfunction 0.3 MB172
Ivermectin-cream-for-rosacea 0.3 MB138
JIA Policy For Adults (Version 1.0) 0.2 MB111
Lamotrigine-for-trigeminal-neuralgia 0.3 MB133
Lamotrigine-for-trigeminal-neuralgia 2 0.3 MB157
Levonorgestrel 13.5mg IUD 0.3 MB121
Lidocaine Plasters For PHN 0.2 MB132
Lidocaine-plasters-for-unlicensed-indications 0.3 MB212
Liothyronine-for-refractory-hypothyroidism 0.2 MB176
Liraglutide-for-obesity 0.3 MB142
Lisdexamfetamine-for-ADHD-in-adults 0.3 MB175
Lisdexamfetamine-for-ADHD-update 0.3 MB131
Lurasidone-for-Schizophrenia 0.3 MB160
Magnaspartate For Hypomagnesaemia 0.3 MB370
Metformin-for-reductionof-risk-or-delay-type-2-daibetes 0.2 MB122
Metformin-for-reductionof-risk-or-delay-type-2-daibetes 2 0.2 MB108
Midazolam-Epistatus-for-seizures 0.2 MB193
Opicapone-for-Parkinsons-disease-v2 0.5 MB162
Ospemifene for VVA 0.2 MB204
Oxycodone-Naloxone-for-Restless-legs 0.3 MB124
Paravit-CF-for-dietary-management-of-patients-with-cystic-fibrosis 0.2 MB530
Patiromer-for-hyperkalaemia 0.3 MB134
Patiromer-for-hyperkalaemia 2 0.3 MB151
Phosphodiesterase Type-5 Inhibitors 0.2 MB121
Pitolisant-for-Narcolepsyv2 0.3 MB148
Policy On Brand Inhaler Prescribing 0.3 MB215
Probiotics And VSL 0.3 MB142
Relvar Ellipta for COPD and asthma in adults 63 KB120
Rituximab-for-AIHA 0.4 MB151
Rituximab-for-ITP 0.4 MB131
Rivaroxaban-10mg-for-DVT-and-PE-and-extended-use 0.1 MB136
Safinamide-for-Parkinsons-disease 0.3 MB155
Second Line Anti-TNF For PsA 0.2 MB135
Second-generation-LA-antipsychotics 0.3 MB159
Secukinumab-for-Palmoplantar-psoriasis 0.3 MB121
Secukinumab-for-Palmoplantar-psoriasis 2 0.3 MB122
Semaglutide for type 2 DM 0.2 MB100
Silk Garments For Eczema And Dermatitis 0.2 MB122
Simbrinza for chronic open angle glaucoma 0.1 MB115
Sodium Oxybate for Narcolepsy with Cataplexy 0.3 MB149
Spironolactone For Acne 0.1 MB169
Subcutaneous Depot Medroxyprogesterone Acetate 0.1 MB131
Tadalafil daily 0.3 MB201
Tapentadol for neuropathic pain in non-palliative care 0.4 MB147
Tapentadol for non-specific pain 0.2 MB132
Testosterone For Female Sexual Dysfunction 0.1 MB109
Tiotropium For Asthma 0.2 MB116
Tocilizumab SC For RA 0.1 MB97
Trelegy inhaler for COPD 0.3 MB193
Trimbow inhaler for COPD 0.4 MB156
Trimbow-inhaler-for-COPD 0.4 MB6
Ulipristal acetate for uterine fibroids 0.5 MB138
Umeclidinium For COPD 0.2 MB109
Vedolizumab For Crohn's Disease 0.2 MB94
Vesomni For Benign Prostatic Hyperplasia 0.1 MB112
Vitamins (inc Renavit) For Dialysis 0.3 MB199
Waterproof Cast Cover Policy 0.1 MB303
Xonvea for nausea and vomiting in pregnancy 0.1 MB101

Medicines guidelines, information sheets, and shared care

Further medicines guidelines are available on Lancashire Medicines Management Group’s website.

Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[3] 0.5 MB50
Asthma treatment guideline for children 0.4 MB38
Azathioprine-Mercaptopurine-SCG-Version 0.2 MB263
BGTS and Meters Guideline Nov16 1.2 MB961
Cannabis-based-medicinal-products-for-pain-POSITION-STATEMENT-version-1.1[1] 0.3 MB51
Ciclosporin-SCG-Version 0.2 MB151
Commissioining Policy For Nutritional Supp Post Bariatirc Surgery Apr13 83 KB158
Conditions-for-which-OTC-items-should-not-routinely-be-prescribed-in-pri .. 0.9 MB215
Dalteparin SCG 2018 0.2 MB151
Electronic-Repeat-Dispensing-guideline 1.7 MB1108
Emollient-Guideline-May-2017 0.2 MB965
Flash Glucose Monitoring policy - L&SC 0.2 MB126
Flowchart-for-Vitamin-D-Deficiency-in-Primary-Care 0.3 MB382
Guidance to support the implementation of the valproate PREVENT programme 0.5 MB217
Guidance-for-7-day-prescriptions-FWCCG-Apr2018 0.5 MB246
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB40
Leflunomide-SCG-Version 0.2 MB152
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB65
MDS Briefing Doc Oct 13 43 KB119
Methotrexate-SCG-Version 0.2 MB279
Mgt-of-Infection-Primary-Care-Guidance-January-2017-version2 0.7 MB709
Patient information - Emollients.steroid.barrier creams 0.2 MB102
Patient information - Emollients.steroid.barrier creams 0.2 MB274
Patient information - spacer devices 0.2 MB141
Patient information - spacer devices 0.2 MB145
Penicillamine-SCG-Version 0.2 MB128
Policy Unlicensed Herbal Vits Mins Supplements 2013 77 KB97
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB63
Prescribing-Nutritional-Supplements-Post-Bariatric-Surgery-Version-1.2[1] 0.3 MB46
Prescribing-Nutritional-Supplements-Post-Bariatric-Surgery-Version-1.2[1] 0.3 MB46
RMOC-Liothyronine-Guidance-v2.0-final-1 0.5 MB104
Sodium-Aurothiomalate-SCG-Version 0.2 MB17
Sulfasalazine 0.2 MB200
Testosterone-Shared-Care-Guideline-Version-1.2[1] 0.3 MB55
Wound Care Formulary 8.2 MB675

Primary care rebate schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started April 2016
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin) – Started September 2018
  • Lixiana (Edoxaban) – Started February 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started July 2019
  • Seretide (Fluticasone / Salmeterol) – Started April 2016
  • Xarelto (Rivaroxaban) – Started October 2019
  • Zoladex (Goserelin) – Started January 2019

Fact and advice sheets

Inhaler Techniques

Inhaler technique videos are available to view online.

Last updated on 18 December 2019 at 11:14 by Senior communications and engagement officer N